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Abstract 
Background: Next generation sequencing has a potential to revolutionize the management of cancer patients 
within the framework of precision oncology. Nevertheless, lack of standardization decelerated entering of the tech-
nology into the clinical testing space. Here we dissected a number of common problems of NGS diagnostics in oncol-
ogy and introduced ways they can be resolved.
Methods: DNA was extracted from 26 formalin fixed paraffin embedded (FFPE) specimens and processed with the 
TrueSeq Amplicon Cancer Panel (Illumina Inc, San Diego, California) targeting 48 cancer-related genes and sequenced 
in single run. Sequencing data were comparatively analyzed by several bioinformatics pipelines.
Results: Libraries yielded sufficient coverage to detect even low prevalent mutations. We found that the number 
of FFPE sequence artifacts significantly correlates with pre-normalization concentration of libraries (rank correlation 
−0.81; p < 1e−10), thus, contributing to sample-specific variant detection cut-offs. Surprisingly, extensive validation 
of EGFR mutation calls by a combination of aligners and variant callers resulted in identification of two false negatives 
and one false positive that were due to complexity of underlying genomic change, confirmed by Sanger sequencing. 
Additionally, the study of the non-EGFR amplicons revealed 33 confirmed unique mutations in 17 genes, with TP53 
being the most frequently mutated. Clinical relevance of these finding is discussed.
Conclusions: Reporting of entire mutational spectrum revealed by targeted sequencing is questionable, at least until 
the clinically-driven guidelines on reporting of somatic mutations are established. The standardization of sequencing 
protocols, especially their data analysis components, requires assay-, disease-, and, in many cases, even sample-spe-
cific customization that could be performed only in cooperation with clinicians.
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Background
The advent of next-generation sequencing and other 
genomic technologies makes it routinely possible today 
to investigate DNA specimens extracted from human 
tumors for gene mutations, chromosomal aberrations, 
differential expression of mRNA and epigenetic altera-
tions. Such detected molecular changes are extensively 
used for integrative analyses aimed at the identifica-
tion of key dysregulated pathways and importantly, the 
establishment of molecular classifiers indispensable for 
targeted therapy and personalized management of malig-
nant disorders [1].
Due to relatively high prevalence of the mutations in 
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to the development of EGFR tyrosine kinase inhibitors 
(EGFR-TKIs), non-small cell lung cancer (NSCLC) has 
become a proving ground for the development of novel 
approaches for molecular typing [2]. Unfortunately, it 
has been established that EGFR-responsive patients with 
activating EGFR mutations eventually develop resist-
ance to the treatment and progress either due to com-
monly acquired T790M mutations or to a variety of other 
molecular changes [3]. On the other hand, initial success 
in exploiting EGFR-TKI sensitivity paved the way for the 
development of other small molecular inhibitors as well 
as widespread introduction of the mutation analyses into 
the molecular subtyping of other tumors. Examples of 
actionable mutations include RAS (KRAS and NRAS), 
BRAF and PI3 K in colorectal cancer [4], BRAF or NRAS 
as well as KIT in malignant melanoma [5], and others. 
These and other genetic alterations continue to gain 
importance in companion diagnostics associated with 
recently marketed targeted therapies and investigational 
drugs [6–8]. As a consequence of efforts invested in this 
area, the number of clinically actionable variations that 
contribute to sensitivity or resistance of tumors to each 
of these drugs is dramatically expanding alongside availa-
ble therapeutic solutions, especially in cases of metastatic 
and refractory diseases. Moreover, the numerous case 
reports demonstrating clinical response to the drugs pre-
scribed off-label based on matching molecular evidence 
ensure the spread of a molecular-informed therapeutic 
decision-concept into oncologist office routine [9–12].
This avalanche of changes was precipitated by the 
replacement of conventional real-time polymerase chain 
reaction (PCR) or direct sequencing by Sanger with Next 
Generation Sequencing (NGS) which has recently revo-
lutionized the field of molecular diagnostics. In addi-
tion to higher sensitivity and remarkable throughput, 
NGS allows gaining non-traditional kinds of information 
about extracted DNA specimen, including the prevalence 
of shorter fragments [13] and the degree of its sequence 
heterogeneity within each locus [14]. Nevertheless, a 
majority of NGS applications are currently limited to 
research use only, while its implementation in clinical 
practice awaits rigorous validation requiring establishing 
Clinical Laboratory Improvement Amendments (CLIA) 
and College of American Pathologists (CAP)-compliant 
performance characteristics. Thus, rapid entering of NGS 
into the space of clinical diagnostics is complicated by a 
number of loosely defined unknowns, including a cover-
age required for confident detection, data quality control, 
benchmarking bioinformatics pipelines currently pro-
ducing discordant variant calls and overall validation of 
the robustness of NGS techniques.
Besides the technical obstacles outlined above, there 
are basic issues with existing “gold standard”: a number of 
novel, potentially very important insights into the tumo-
rigenesis were gained by massive parallel sequencing for 
the first time, as they originated from observations that 
cannot be performed earlier due to intrinsic shortcom-
ings of Sanger sequencing and conventional PCR. As 
example we can point to the clinical significance of intra-
tumor heterogeneity with therapy resistance mutations 
being present with low prevalence already at the pretreat-
ment assessment [15]. Currently, there is no consensus 
on how to differentiate these mutations from the FFPE 
artifacts [16]. Another set of important issues are inci-
dental findings that may be revealed by NGS reads even 
if they were targeted for detecting of the mutation spec-
trum defined beforehand [17]. Examples of such inci-
dental findings may include novel, not yet characterize 
mutations within target gene, common variants that may 
influence risks of other diseases or even germline muta-
tions [18]. Such findings are generally hard to interpret 
in terms of their clinical relevance and lack a consensus 
on whether they should be communicated to physician or 
the patient at all. Finally, NGS allows one to detect muta-
tions, which remain unseen if not being targeted by anal-
ysis. For instance, owing to implementation of the NGS 
into clinical practice, EGFR kinase domain duplication 
mutation has recently emerged as novel EGFR TKI sen-
sitizing variant [19].
Despite recent publications of a number of clinical 
NGS guidelines clinical test development by a variety 
of organizations including American College of Medi-
cal Genetics [20] and College of American Pathologist 
[21], overcoming the obstacles mentioned above remains 
challenging, especially when the detected mutations are 
somatic, as the majority of guidelines are established only 
for the reporting of germline mutations. It is likely that 
both general recommendations and relevant protocols 
for sequencing, data analysis and clinical interpretation 
will continue to evolve in the process of sharing the out-
comes of the tailoring of commercially available tests to 
the needs of particular practice or country, or panel cus-
tomization. In this paper we describe particular obsta-
cles we encountered while analyzing the clinical NGS 
dataset obtained using the TruSeq Amplicon—Cancer 




Thirteen archived clinical tumor specimens from twelve 
lung cancer patients treated at Blokhin Russian Cancer 
Research Centre (RCRC) in 2014–2015 were randomly 
selected from respective existing registry. Another set of 
13 samples was retrospectively randomly selected from a 
collection of Russian Scientific Center of Roentgenology 
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and Radiology (RSCRR). Specimens of the latter set had 
already been screened for the presence of EGFR muta-
tions; hence, this RSCRR set of samples was enriched 
with EGFR positive patients by design. Overall, we stud-
ied 26 tumor specimens including lung adenocarcinoma 
(n =  11, 42%), squamous cell carcinoma (n =  11, 42%) 
and the tumors of mixed or unknown histology (n =  4, 
16%). The study protocol was approved by Atlas Biomed 
Internal Review Board. Written informed consent was 
provided by all patients at inception of the study, all anal-
yses were based on archival data and stored in database 
with no connections to the patient identifiers.
DNA extraction and sample quality control
Genomic DNA was extracted from formalin fixed, par-
affin embedded (FFPE) tissues with the QIAamp DNA 
FFPE kit (Qiagen, USA) according to the manufactur-
er’s instructions and was eluted in a 25 μL volume. The 
extracted DNA specimens were further quantified using 
the Qubit dsDNA HS assay kit (Life Technologies/Fisher 
Scientific, USA) and samples with DNA concentration 
lower 50  ng/μl were concentrated to this value. DNA 
quality and quantity were further assessed using the 
Illumina FFPE QC Kit according to the manufacturer’s 
instructions.
Library preparation and quality control
Sequencing libraries were prepared with the TSACP 
(Illumina, San Diego, USA), according to manufac-
turer’s protocol. Briefly, an oligo pool was hybridized 
to each genomic DNA sample. Following the removal 
of unbound oligos, target regions of interest flanked by 
sequences required for amplification were generated by 
extension and ligation and libraries were further PCR 
amplified. Library quality was assessed on a 2100 Bio-
analyzer (Agilent Technologies, Santa Clara, California). 
Prior sequencing, the libraries were normalized follow-
ing the manufacturer protocol and equal volumes were 
pooled to generate the final sequencing library. Primer 
panel designed to generate 212 amplicons within 48 can-
cer-related genes: ABL1, AKT1, ALK, APC, ATM, BRAF, 
CDH1, CDKN2A, CSF1R, CTNNB1, EGFR, ERBB2, 
ERBB4, FBXW7, FGFR1, FGFR2, FGFR3, FLT3, GNA11, 
GNAQ, GNAS, HNF1A, HRAS, IDH1, JAK2, JAK3, KDR, 
KIT, KRAS, MET, MLH1, MPL, NOTCH1, NPM1, NRAS, 
PDGFRA, PIK3CA, PTEN, PTPN11, RB1, RET, SMAD4, 
SMARCB1, SMO, SRC, STK11, TP53, and VHL.
Sequencing and data analysis
Pooled libraries were sequenced using MiSeqDx (llumina) 
with a 2 × 150 paired-end sequencing design. Image pro-
cessing and fastq file generation were further performed 
with CASAVA version 1.8.2 and RTA version 1.17.28 
(Illumina). Reads were preprocessed for a removal of low-
quality and too short nucleotide sequences using the Prin-
seq-lite program [22]. Minimum mean read quality score 
was set to Q30, and minimum length to 75 base pairs. 
Remaining paired-end reads were mapped to the GRCh37.
p13 human genome employing Bowtie2 [23] software with 
varying parameters. After alignment, an exclusion of prim-
ers was performed employing in-house software. SAMtools 
(version 1.2) [24] was applied for the calling of germline 
variants, while somatic mutations were identified by Strelka 
(version 1.014) [25], Varscan (version 2.3.9) [26], ScalPel 
(version 0.5.3) [27] and Illumina Somatic Variant Caller 
(SVC) (version 3.1.6.4). GATK version 3.6 [28] was addi-
tionally used for indel realignment and other analysis. Ger-
mline polymorphisms were discriminated from the somatic 
based on their frequencies in human populations and pres-
ence in dbSNP [29] and COSMIC [30] databases. Recur-
rent artifact variant calls were discarded from the analysis 
employing in-house software. Protein variant annotation 
was performed using ANNOVAR [31], with non-coding 
or synonymous mutations discarded from further analysis. 
Copy number variations were detected using CNVPan-
elizer [32].
Mutation verification
Following NGS sequencing, EGFR and KRAS (including 
codons 12, 13) mutations in samples from the RCRC set 
as well as KRAS mutations from RSCRR set were vali-
dated either by Sanger sequencing or Real-Time PCR. 
Samples from RSCRR set were pre-screened for EGFR 
mutations and, thus, not required further validation with 
orthogonal methods. EGFR mutations (including exons 
18–21) were examined by Sanger Sequencing. Primer 
pairs were 5′-CTGAGGTGACCCTTGTCTCTG-3′ and 
5′-CCAAACACTCAGTGAAAC-3′, 5′-TGCCAGT-
TAACGTCTTCCTT-3′ and 5′-CAGGGTCTAGAGCA-
GAGCAG-3′, 5′-CATTCATGCGTCTTCACCTG-3′ and 
5′-TTATCTCCCCTCCCCGTATC-3′, and 5′-TGATCT-
GTCCCTCACAGCAG-3′ and 5′-GGCTGACCTAAA-
GCCACCTC-3′ for exons 18, 19, 20 and 21 respectively. 
Thermal cycling conditions included 5  min at 95  °C 
followed by 35 cycles of 95  °C for 30  s, 60  °C for 30  s, 
72  °C for 1  min and one cycle of 72  °C for 7  min. The 
PCR products were further purified with USB ExoSapit 
(GE Healthcare, Uppsala, Sweden) followed by cycle 
sequencing with the BigDye Terminator version 3.1 cycle 
sequencing kit (Applied Biosystems) according to the 
manufacturer’s protocol and resolved on an ABI 3500xL 
sequencer (Applied Biosystems). Sequence chromato-
grams were analyzed by Sequencher software (Gene 
Codes Corp, Ann Arbor, MI), followed by manual review. 
KRAS codon 12, 13 mutations were examined by pyrose-
quencing as described previously [33].
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Results
NGS sequencing results
We performed high-throughput sequencing employing 
amplicon library construction with primer panel target-
ing 212 regions of 48 oncogenes and tumor suppressor 
genes in 26 FFPE tumor samples. Approximately 91% of 
all reads from the Illumina MiSeq sequencer were suc-
cessfully mapped to the reference genome, with the 
coverage depth of 720×  for 82% of the target bases and 
220× for 93% of the target bases. Across the samples, the 
overall mean coverage was 2084× and median—2016×. 
The frequency of amplicon drop-out was at 0.5%. These 
results indicate that a coverage resolution was high 
enough to identify somatic point mutations and short 
indels as well as the copy number variations.
In contrast to high coverage observed across entire 
panel, one or more amplicons within the genes CDKN2A, 
FGFR3, GNA11, HRAS, MPL, SRC, STK11, VHL and 
SMO displayed relatively low depth of the coverage in 
substantial proportion of DNA specimens. For many 
samples, amplicon-specific coverages were seen to drop 
as low as 140×. An extremely low coverage at less than 
4% of the average amounts of reads across all amplicons 
and samples with the mean of 51× was detected in MPL 
gene, which, to the best of our knowledge, was not previ-
ously noted as deviating from average. Additionally, the 
mining of existing literature highlights that the sequenc-
ing of some regions within RB1, HNF1A, NOTCH1 
and RET might also result in consistently low coverage 
[34, 35]. In our study, uniformly high coverage of these 
genes was observed across all samples. It is possible that 
amplicon-specific coverage may vary form run to run, or 
depend on the batch of the primers or the library kit, or 
clinic-specific protocol of FFPE preparation.
For the mutations informing the treatment strategy 
specifically in the lung cancer, the coverage was consist-
ently high, with the lower border of the 99.9% CI of cov-
erage depth 1.5 times higher than the average across all 
the genes comprising TCASP panel. This quality of the 
coverage allowed us to proceed with other types of analy-
sis aimed at highlighting problematic aspects of NGS 
testing in clinical oncology.
DNA degradation artifacts may limit the accuracy of the 
test
The quantities and the quality of DNA extracted from 
tumor biopsies might vary from sample to sample. In par-
ticular, the tissue fixation process might result in exten-
sive DNA degradation and, therefore, to introduction 
of artifactual bases. According to previous observations 
made using FFPE samples, false positive findings are 
predominantly represented by C:G > T:A base substitu-
tions with frequencies in range of 0–10% of the covering 
reads [36, 37]. Typical assessment by Sanger sequencing 
is insensitive to the variants present at frequencies lower 
than 20% [38]. In contrast, the diagnostic with NGS 
overcomes this obstacle by increase in the coverage pro-
portional to the rarity of the variant. Given that clinical 
guidelines recommend detection of the variants that are 
present in 5 or 2.5% of the covering reads for mutations 
associated with the response and the resistance, respec-
tively, poses the problem of discrimination between veri-
fiable mutations and artifacts of the FFPE processing.
Across all samples studied, we identified a bit over 3300 
mutations with the mean C > T base substitution propor-
tion of 44%. Among these, approximately 3200 mutations 
were detected with the allele frequency ranges of 0–10%. 
Yet, four out of 26 FFPE specimens displayed high mutation 
rate with average allele frequencies of more than 10%, with 
eight, seventeen, forty and fifty-six of these highly preva-
lent mutations detected in same DNA sample, respectively 
(Fig.  1a). Importantly, a majority of these highly frequent 
mutations were C > T substitutions. In four specimens of 
interest, they were at 34, 50, 63 and 65%, respectively. In 
each sample with aberrant count of high prevalent sub-
stitution, prevalence of the C  >  T substitutions in allele 
frequency range from 0 to 10% tended to be lower as com-
pared with the other samples (with p value ranging from 
0.015 to 2e−7), thus, demonstrating a peculiar trend.
In addition, for three out of four samples with high 
mutation loads, the coverage was significantly reduced 
due to low total read counts (p value ranging from 0.026 
to 5e−3) (Fig.  1c). Similarly, the percentages of reads 
passing base quality filters for these three samples were 
also smaller (Fig.  1b). For one out of four samples with 
high mutation loads, the coverage was trending along 
with the majority of samples (p-value = 0.61).
An insight on initial DNA quality may be derived by 
assessing sequencing library concentrations before the 
normalization. In specimens of interest, these concen-
trations were at 1.0, 1.0, 1.3 and 1.3 ng/μl, while for the 
rest the lowest sequencing library concentration was 
at 1.9  ng/μl (p  <  1e−5, by Wilcoxon-Mann–Whitney 
Test). Furthermore, the DNA specimens converted to 
the libraries with high pre-normalization concentrations 
displayed lowest total mutation counts (Fig. 2). It seems 
that pre-normalization concentrations of libraries are 
indicative of the degree of DNA degradation in a given 
specimen and could be useful for calculations of sample-
specific expected rates of artifactual findings.
DNA specimens may yield multiple somatic mutations 
associated with potentially important incidental findings
Owing to advances in the development of TKIs that tar-
get EGFR, the screening for point mutations within EGFR 
already became an integral part of routine examination 
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of lung tumor specimens [39]. However, recent studies 
indicated that the mutations in the genes of MAPK and 
PI3K-AKT pathways may influence the response to EGFR 
TKI and, therefore, are useful as both predictive and 
prognostic markers. These observations prompted us to 
perform retrospective validation of the presence of NGS-
detected somatic variations in PIK3CA, BRAF, KRAS, 
NRAS, HER2, ALK and MET genes employing Sanger 
sequencing or quantitative Real-Time PCR.
In a study of 26 FFPE tumor specimens, activating EGFR 
mutations associated with sensitivity to the EGFR TKI 
therapy were detected in eight cases. Among these, three 
tumor specimens were found to harbor coding frame 
point mutation p.L858R (or p.Leu858Arg), four tumors 
had the deletion of exon 19 and a single sample had an 
insertion of exon 19. The EGFR TKI resistance associated 
mutation p.T790M (or p.Thr790Met) was detected in a 
single sample with p.L8585R variant of EGFR.
Fig. 1 The description of potential artifacts detected in FFPE samples. a Mutation counts (solid line) and C/T base substitution rates (bar histogram) 
at two allele frequency ranges across all samples were sorted according to the total mutation counts for given specimen. There was a trend of 
increasing C/T substitution rate along with total mutation count. Four samples did not follow this trend. Only these samples and none of the others 
showed very high mutation counts at allele frequencies of more than 10% with the accordingly high C/T substitution rate in this range. Pre-nor-
malization library concentrations were low for all four samples in question. b Per-base Phred quality scores for each position across all samples. Four 
samples with high mutation counts at allele frequencies of more than 10% are highlighted by bold lines. c Overall sequencing results for all samples. 
Four samples of interest are respectively highlighted
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As TSACP panel covers 48 oncogenes and tumor sup-
pressor genes, we were able to extend the analysis of 26 
FFPE lung cancer specimens beyond EGFR gene. Assum-
ing that non-EGFR mutations gain their therapeutic sig-
nificance only when present in a relatively major clone, 
the allele frequency cutoffs were redefined at 10%. After 
filtering out all non-recurrent mutations detected exclu-
sively in samples with low pre-normalization library 
concentrations, we identified 33 unique non-EGFR point 
mutations including 25 single nucleotide variations and 
8 small insertions/deletions (Table 1). Of these, 28 vari-
ants were likely of somatic origin, and further 5 were 
likely germline. In each particular case, the determina-
tion was made after taking into account the presence of 
the mutation in dbSNP and COSMIC databases, and the 
reported prevalence in human populations or in cancer 
specimens. The highest rate of somatic mutations was 
observed in TP53 gene with eleven alterations detected. 
Overall, previously described non-EGFR mutations 
known to modify the response to drug therapy were 
identified in 8 patients, and including the mutations 
in TP53, KRAS, PIK3CA, HRAS, AKT1 and CTNNB1. 
Of particular interest, the mutations of KRAS were 
detected in 5 samples including one sample with simul-
taneous presence of two KRAS mutations (p.Gly12Cys 
and p.Ala146Thr), though only two of the KRAS positive 
samples harbored high prevalent mutations, while the 
rest, thus, could not be validated with orthogonal meth-
ods. Additionally, PIK3CA mutation p.Glu545Lys was 
detected in single case.
Standard analytic pipelines as a source of possible false 
positive and false negative findings
Importantly, two Sanger-confirmed EGFR mutations 
were identified by NGS sequencing, but missed by SVC 
that is built into the MiSeq Reporter v1.3  +  software 
available in Ilumina maintained BaseSpace™. In particu-
lar, inframe deletion in exon 19 that was compounded 
with single nucleotide variant, a complex mutation 
p.Glu746_Ser752delinsAlaPhe was mislabeled as two 
frameshift mutations p.Gly746fs and p.Ser752fs. Though 
these two molecular changes were found within the same 
haplotype and, therefore, should be designed as complex 
mutation, SVC provided no information on this haplo-
type. Since SVC-reported frameshift deletion lead to total 
inactivation of the protein rather than activated EGFR 
that is generated by Sanger-confirmed inframe deletion 
in exon 19, incorrected calling resulted in a false-negative 
result. In clinical setting, this false positive would lead 
to missed opportunity for EGFR TKI treatment. On the 
other hand, this mutation was successfully detected using 
Bowtie2 in conjunction with Strelka, Varscan2 and Scal-
pel pipelines.
Another example of the false negative result was a pre-
viously described [52] insertion in exon 19 (p.Ile744_
Lys745insLysIleProValAlaIle) that is located 138 bp away 
from the end of the amplicon. Therefore, at final cycles, 
reverse reads end within the insertion sequence. Moreo-
ver, 3′ end of insertion sequence is similar to the refer-
ence sequence. Thus, when BWA [53] or Bowtie2 are 
run with the default parameters, the reverse reads got 
misaligned and incorrectly confirm another, previously 
undescribed shorter insertion. The presence of two inser-
tions in both strand was not reported due to strand bias, 
and, as a consequence, this mutation was not reported 
by any tested variant caller, including Strelka, Varscan2 
and Scalpel and also Illumina Somatic Variant Caller. 
However, after adjusting alignment gap open penalty to 
high and gap extension penalty to low, which resulted in 
proper alignment, this mutation was successfully identi-
fied. Interestingly, realignment with GATK and its stand-
ard parameters also allowed successful detection of this 
mutation, indicating that this aligner should be recom-
mended either as a primary alignment tool or as a backup 
for independent validation of the findings.
In one patient, the sequencing of EGFR amplicons 
resulted in calling of both p.G719V (or p.Gly719Val) 
mutation and p.Leu718fs deletion that were present 
within the same copy of the gene. According to NGS 
results, all the sequencing reads with mutation p.G719V 
also had mutation p.Leu718fs, while all other reads from 
the same amplicon were mutation-free. While the muta-
tion in codon 719 confers the response to EGFR TKI, 
the frameshift deletion in the preceding codon results in 
Fig. 2 The mutations counts correlate with the pre-normalization 
library concentrations. Samples with highest pre-normalization library 
concentrations were found to harbor fewer mutations, most probably 
due to lower amounts of DNA degradation artifacts, while samples 
with lowest pre-normalization library concentrations harbored a 
diverse spectrum of the detectable variants (Spearman’s rank correla-
tion −0.81; p < 1e−10)
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altered protein sequence and premature stop. Therefore, 
even though p.G719V mutation is present in the genome, 
it does not express at the level of the protein, and, there-
fore, the therapy with EGFR TKIs would not be effective. 
Thus, the detection of p.G719V is, indeed, a false posi-
tive, despite its proper identification. Manual analysis of 
the reads allowed the phasing of p.Leu718fs into the same 
haplotype, and the correct assessment of the combined 
effect of both molecular changes.
The Detection of Somatic Copy Number Variations
Even in absence of the sequenced control samples, the 
Copy Number Variations (CNVs) may be identified by 
employing bootstrapping that generates control sets by 
randomly subsampling experimental ones with replace-
ment. Using this approach, in two specimens an amplifi-
cation of EGFR was detected, with respective increase in 
its copy number by 5.7 and 17.6 folds. In both cases, this 
molecular event was detected across all 8 TSACP ampli-
cons. Though EGFR amplification does not yield consist-
ent predictive power as previously been shown [54–56], 
it still may serve as important prognostic marker [57]. 
In another patient, a significant increase in MET gene 
coverage across its five TSACP amplicons was detected. 
Typically, the amplification of MET is defined by Fluo-
rescent In Situ Hybridization (FISH) as MET:CEP7 ratio 
that is greater than 2.2. This and higher degrees of ampli-
fications are associated with either primary or acquired 
resistance to the therapy with EGFR TKIs as well as with 
enhanced tumorigenesis, invasion and metastasis [58–
61]. Moreover, high levels of MET amplification defined 
as MET:CEP7  >  5 were previously identified as action-
able driver mutations predicting sensitivity of the tumor 
to the inhibitors of kinase MET,  including crizotinib, 
currently approved for the treatment of ALK or ROS1-
rearranged lung cancers [62]. To investigate the levels of 
Table 1 Identified exonic mutations in non-EGFR genes
Synonymous variants, common polymorphisms (KDR p.Q472H, KIT p.M541L, TP53 p.P72R, HNF1A p.G226A) as well as presumably germline variants (ATM p.F858L) are 
not shown. Frameshift and nonsense variants were accounted as deleterious
For variant annotation, the following references were used: ABL1—NP_005148.2; AKT1—NP_005154.2; ATM—NP_000042.3; BRAF—NP_004324.2; CTNNB1—
NP_001091679.1; EGFR—NP_005219.2; HNF1A—NP_000536.5; HRAS—NP_001123914.1; KDR—NP_002244.1; KIT—NP_000213.1; KRAS—NP_004976.2; MLH1—
NP_000240.1; NOTCH1—NP_060087.3; PIK3CA—NP_006209.2; RB1—NP_000312.2; STK11—NP_000446.1; TP53—NP_000537.3; VHL—NP_000542.1
LUAD lung adenocarcinoma, LUSC squamous cell lung carcinoma, NSCLC non-small cell lung cancer of unknown or mixed histology
Gene Protein sequence variation Patient Tumor histology Mutant allele frequency (%) Variant impact
HNF1A p.Gly306 fs 5 LUAD 15 Deleterious
TP53 p.Gly272 fs 9 LUAD 15 Deleterious
TP53 p.Val173Met 10 LUAD 17 Deleterious [40]
MLH1 p.Ser406Asn 12 LUAD 15 Deleterious [41]
KIT p.Glu76Asp 12 LUAD 50 Unknown
TP53 p.Leu206_Arg209del 12 LUAD 70 Unknown
ABL1 p.Thr243Ile 65 LUAD 15 Unknown
KRAS p.Gly12Cys 65 LUAD 31 Activated
CTNNB1 p.Ser33Phe 89 LUAD 11 Activated [42]
KRAS p.Gly12Asp 90 LUAD 30 Activated
TP53 p.Cys238Tyr 91 LUSC 44 Deleterious [40]
NOTCH1 p.Leu1600Pro 105 LUSC 11 Activated [43]
TP53 p.Arg175 fs 106 LUSC 56 Deleterious
HRAS p.Gly13Val 120 LUSC 82 Activated [44]
AKT1 p.Glu17Lys 120 LUSC 4 Activated [45]
TP53 p.Ser215Gly 131 LUSC 45 Deleterious [40]
ATM p.Asn856Ile 140 LUSC 10 Unknown
TP53 p.His214Arg 150 LUSC 33 Deleterious [40]
TP53 p.Arg337Pro 152 LUSC 50 Deleterious [40]
VHL p.Lys171Arg 161 NSCLC 18 Deleterious [46, 47]
TP53 p.Arg248Gln 161 NSCLC 31 Deleterious [48, 49]
TP53 p.Ser185 fs 187 NSCLC 17 Deleterious
RB1 p.Ser576 fs 187 NSCLC 18 Deleterious
PIK3CA p.Glu545Lys 193 NSCLC 15 Activated [50, 51]
TP53 p.Tyr205Asp 193 NSCLC 22 Deleterious [40]
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MET amplification in specimen of interest, we normal-
ized the coverage by combining amplicons covering three 
other genes located on chromosome 7, EGFR, BRAF 
and SMO. The level of presumable amplification that we 
observed were low, at 1.65× before normalization and 
at 1.6× after normalization, thus, indicating that that, in 
specimen of study, amplification of MET had not reached 
clinical significance [63].
Discussion
Advances in target therapy development have introduced 
an opportunity of informed management of the malig-
nant disorders using the guidance of their molecular 
profiles. Most conveniently, NGS techniques are capa-
ble of the detection of multiple genetic alterations at 
once, while retaining both an accuracy, informativeness 
and cost-efficiency. Despite the advantages that NGS 
techniques provides over conventional methods, their 
implementation often meets difficulties and should be 
accompanied equivalency of its analytical performance. 
For numerous targeted panels, a number of published 
NGS protocols have already demonstrated satisfactory 
results. Nevertheless, some of the obstacles remain.
In this study, TSACP technology was tested in the 
retrospective analysis of somatic mutations in 26 FFPE 
specimens collected from NSCLC patients. All hotspot 
alterations detected in clinically relevant genes, includ-
ing EGFR, PIK3CA, BRAF, KRAS, NRAS, ERBB2, ALK 
and MET, were successfully validated by Sanger sequenc-
ing or Real-Time PCR. EGFR mutations were detected 
in eight patients out of 25, while high-prevalent muta-
tions of KRAS were detected in two, and low prevalent 
in additional three samples. Some findings were less 
than typical. For example, one of the specimens har-
bored both activating EGFR p.L858R mutation and 
PIK3CA p.Glu545Lys mutation that was present at allele 
frequency of 15%. Another specimen with the dele-
tion of EGFR exon 19 also harbored KRAS p.Gly12Val 
mutation that was detected at mutant allele frequency 
of 6%. Though cases of concomitant presence of EGFR 
and KRAS or PIK3CA mutations have already been 
described, they are very rare. In both cases, compound 
mutations were below the limits for the detection by 
Sanger sequencing [38]. Importantly, the shortcomings 
of Sanger sequencing and other conventional methods 
influence historic accumulation of the data on cancer 
related variants with lower prevalence and, therefore, 
provide a ground for underrating of these, potentially 
important, findings. Widespread use of high-sensitive 
mutation detection techniques should be accompa-
nied by appropriate data analysis and their deposition 
into panel-specific databases that may facilitate further 
insights on co-occurrences of various mutations, their 
allelic frequencies and clinical significance of each find-
ing. The latter aspect remains the most challenging due 
to common underreporting of the minor alleles.
Clear clinical need of identification of the low-prev-
alent mutations remains, at least in part, unmet due to 
use of FFPE for the tumor specimen long-term preserva-
tion. FFPE is convenient, cost-effective, and efficient for 
immunohistochemical staining and morphology analy-
ses. In the meantime, it is unsuitable for the high reso-
lution mutation analysis due to DNA damage artifacts 
introduced by fixation and paraffin-embedding proce-
dures. In this study, the tissues were fixed using uniform 
protocol implemented at two independent laboratories. 
These FFPE samples are routinely produced by clinical 
workflow.
With the average coverage of 2084×, at least in theory, 
we were capable to detect mutations at allele frequencies 
of 1%. According to TCGA data, both lung adenocarci-
noma and squamous cell lung cancer specimens harbor 
approximately 9 mutations per Mb, or, on average, 0.36 
mutations per 40  kb, or the size of the TSACP panel 
[64, 65]. Considering that the sequencing efforts are 
concentrated in areas intrinsically important for tumo-
rigenesis and, therefore, undergoing the selective pres-
sure, one may expect the mutation rates a bit higher. In 
our experiment, we detected a bit over 500 variants per 
40 kb of sequenced DNA in each sample, on average. In 
both histological types of lung cancer samples described 
in TCGA, the proportion of C  >  T substitutions was at 
approximately 20%, while in experimentally assessed 
DNA specimens extracted from FFPE blocks the percent-
age of C > T base substitutions was substantially higher 
(p < 0.01 for both lung adenocarcinoma or squamous cell 
carcinoma, by t-test), in one sample reaching 74%. More-
over, a majority of detected variants were present at fre-
quencies of 0–10% (Fig. 1). Hence, we have to conclude 
that these changes are more likely to represent DNA 
degradation artifacts rather than to be a consequence of 
intratumor heterogeneity [66].
As it was already shown previously, in a majority of 
FFPE specimens, DNA degradation artifacts are seen 
in the allele frequency range of 0–10% and represented 
predominantly by C:G > T:A nucleotide substitutions. It 
is tempting to dismiss these artifacts by applying simple 
allele frequency threshold. Nevertheless, in our study 
we observed that some of the specimens produced a 
number of artifactual findings presenting as high fre-
quency variants. We noted that the processing of these 
specimens resulted in remarkably low pre-normalization 
concentrations of libraries. One of these specimens har-
bored hotspot AKT1 p.E17K (or p.Glu17Lys) variant at 
allele frequency of 4%, which significance was overshad-
owed by highly prevalent artifacts. Therefore, limiting 
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the analysis only to known hotspots while assuming 
that probability of artifactual detection of the molecular 
lesion within known hotspot is low would not resolve the 
reporting dilemma.
In attempt to determine the applicability of using sim-
ple mutation allele frequency cut-offs for sorting out 
FFPE derived artefacts, the relationship of allele frequen-
cies and mutation counts at these frequencies was stud-
ied. Figure  3 illustrates that the DNA specimens that 
resulted in the production of libraries with high pre-nor-
malization concentrations demonstrate a steady decrease 
in respective mutation counts along with growing fre-
quencies of individual alleles. In contrast, the sequenc-
ing of DNA specimens that resulted in the production 
of libraries with low pre-normalization concentrations 
identified subset of called variants, with allele frequen-
cies ranging between 9 and 20% (p < 4e−3). This subset 
could not be clearly filtered by recommended reportable 
allelic frequency ranges for an analysis of FFPE derived 
DNA specimens. Thus, it is more difficult to deal with, as 
it could be identified only when taking into account the 
range of pre-normalization concentrations for libraries 
entered into the sequencing run.
In this situation, an assessment of pre-normaliza-
tion concentrations of libraries may be part for the 
sample-specific calculation of the detection cut-offs. 
Moreover, these cut-offs may be even mutation-specific: 
if the frequency of allele in question is below 10%, but its 
nature is different from C > T, the probabilities that the 
variant originated in damaged DNA base would be rela-
tively low. On the other hand, there is some evidence that 
the DNA degradation artifacts are not exclusively repre-
sented by substitutions C:G  >  T:A. For example, when 
we applied Fisher’s exact test to mutation counts for all 
nucleotide substitutions detected in our samples and 
their frequency ranges, we observed that A  >  T, T  >  C, 
G  >  T and G  >  C substitutions may also be associated 
with increased probability of being FFPE derived arte-
facts, while for G > C and T > C substitutions these prob-
abilities were significantly decreased (data not shown).
This means that instead of simple empirical rules based 
on allele frequency cut-offs or nucleotide substitution 
types, this task may require supervised machine learning 
approaches executed on paired tumor samples obtained 
from the same patient and validated on the similar data-
sets. In any case, the necessity of further research in this 
field is clear since formalin fixation remains the most 
common technique for long-term preservation of cancer 
specimens. An alternative is in introduction of additional 
library preparation steps that may reduce the counts of 
Fig. 3 The counts of mutations detected in various ranges of allele frequencies. Samples with pre-normalization library concentrations as low as 
1.5 ng/μl were shown to yield substantial amounts of presumably artifactual variants with high prevalence in the sequencing reads. These muta-
tions could not be filtered out by using preset frequency thresholds
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FFPE-related artifacts, for example, by treating samples 
with uracil-DNA glycosylase [16]. It should be also noted 
that an introduction of additional sample processing 
steps may influence sequencing outputs, the interpreta-
tion of these outputs, and, therefore, clinical decision. 
In particular, the treatment of samples with uracil-DNA 
glycosylase may significantly impact mutation allele fre-
quencies [67], which, in turn, are paramount for evalu-
ating potential benefits from the targeted therapy [68]. 
Therefore, an introduction of additional enzymatic pro-
cessing requires a comparative study and a through vali-
dation before its adoption into the routine.
Despite relatively small size of the study, a single false 
positive and two false negative calls of the EGFR muta-
tions were uncovered. Importantly, using of two or more 
combinations of aligning software and further indel rea-
lignment with variant callers may help to solve these dis-
crepancies. It is important to note that, for the specimens 
of question, using of unified and, therefore, simplified 
analysis protocols would definitely result in non-optimal 
management of the disease. Aiming at eventual replace-
ment of conventional molecular diagnostics with high-
throughput NGS-based methods of NGS, we should 
remember that commonly used analytic pipelines may 
remain inefficient when dealing with insertions and dele-
tions, thus, justifying the need for in-house pipelines and 
scripts.
In addition to the mutation in known hotspots, a total 
of 24 unique somatic mutations were detected in 26 stud-
ied samples. TP53 was the most mutated gene with a 
total of 11 alterations detected in 11 patients. Assuming 
that these non-hotspot mutations were never prospec-
tively validated in NSCLC, and, therefore, never received 
a designation of actionable item, all of these would have 
to be classified as incidental findings. Among these were 
the molecular changes validated as actionable in other 
types of the tumors, or the mutations that influence the 
prognosis but not yet targeted by approved medicines 
and non-hotspot mutations associated with treatment 
resistance. It seems that the validation of these mutations 
as actionable may be hastened by deposition of these, 
not-yet-actionable findings into panel-specific databases 
that may mined for further insights into their clinical 
significance.
In addition, a total of five presumably germline coding 
frame variants were identified, including KDR p.Q472H 
(or p.Gln472His), KIT p.M541L (or p.Met541Leu), 
TP53 p.P72R (or p.Pro72Arg), HNF1A p.G226A (or 
p.Gly226Ala) and ATM p.F858L (or p.Phe858Leu). For 
a majority of these variants, the frequencies in human 
populations were high, thus indicating that these vari-
ant were likely inherited form the parent. Nevertheless, it 
may be possible that the presence of one or more of these 
variants in patient’ genome may have an impact on tumo-
rigenesis or on the therapy outcomes. For instance, the 
presence of KDR p.Q472H variant was previously shown 
to alter tumor angiogenesis and vascularization [69]. 
Moreover, in vitro studies showed that the sensitivity to 
variant-harboring cells to VEGFR2 inhibition is higher 
than that in the cells with wild-type genotype [69, 70]. As 
compared to the most common TP53-72P variant, the 
presence of TP53-72R protein augments apoptosis up 
to 15-folds, thus, to some degree protecting individual 
from neoplastic development and, possibly, modifying 
the response to conventional chemotherapy [71]. Though 
prognostic value of this polymorphism have already been 
shown in several case series and prospective studies in 
several tumor types [72, 73], its predictive role remains 
not well understood [74–76]. Furthermore, KIT p.M541L 
variant was reported to confer an enhanced proliferative 
response to low levels of stem cell factor, though evi-
dences supporting its predictive effect are controversial 
[77–83]. Finally, despite relatively low frequency of the 
ATM p.F858L variant in human populations described 
within the 1000 Genomes Project (0.5%), according to 
previous publications, its nature is likely germline. Inter-
estingly, in large population based cohorts, this vari-
ant was associated with an increase in risks for prostate 
[84], breast [85] and colorectal [86] carcinomas as well 
as chronic lymphocytic leukemia [87]. Additionally, in 
patients with childhood T-lineage acute lymphoblastic 
leukemia, carrying ATM p.F858L was associated with a 
variety of negative predictors, and worsened outcomes 
[88].
It is clear that accumulation of the knowledge on the 
prevalence of these variants in tumor specimens may 
lead to eventual recognition of these incidental findings 
as relevant to either personalized selection of therapeu-
tic strategy, or to the risks of the cancer development in 
the relatives of the proband. No database currently accu-
mulates these kinds of findings in depersonalized form. 
Therefore, in a majority of the cases, these germline vari-
ants remain unreported and, therefore, missed for fur-
ther analysis. In our opinion, creation of panel-specific 
incidental finding databases is warranted, as it may has-
ten overall understanding of tumorigenesis.
Conclusion
Reporting of entire mutational spectrum revealed by tar-
geted sequencing is questionable, at least until the clini-
cally-driven guidelines on reporting of somatic mutations 
are established. The need for the development of panel-
specific databases allowing analysis of co-occurrence 
and relevance of somatic mutations, CNVs and germline 
variants in de-identified form is evident. Further stand-
ardization of sequencing protocols, especially their data 
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analysis components, may require assay-, disease-, and, 
in many cases, even sample-specific customization that 
could be performed only in cooperation with clinicians.
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